Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.54 |
| ▸ | CDK4 | P11802 | 4/20 | 0.54 |
| ▸ | CCND1 | P24385 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 5/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4549836 | 0.84 | CDK2 (0.56) | CDK2CCNE1CDK4CCND1RPS6KA3 | |
| SCHEMBL4549878 | 0.84 | CDK2 (0.56) | CDK2CCNE1CDK4CCND1RPS6KA3 | |
| SCHEMBL16074639 | 0.71 | CDK2 (1.00) | CDK2CCNE1CDK4CCND1 | |
| SCHEMBL15249257 | 0.71 | CDK2 (1.00) | CDK2CCNE1CDK4CCND1 | |
| SCHEMBL10082757 | 0.71 | CDK2 (1.00) | CDK2CCNE1CDK4CCND1 | |
| SCHEMBL16074640 | 0.71 | CDK2 (1.00) | CDK2CCNE1CDK4CCND1 | |
| SCHEMBL15249256 | 0.71 | CDK2 (1.00) | CDK2CCNE1CDK4CCND1 | |
| SCHEMBL22005395 | 0.71 | CDK2 (1.00) | CDK2CCNE1CDK4CCND1 | |
| SCHEMBL15249217 | 0.67 | CDK2 (0.54) | CDK2CCNE1CDK4CCND1RPS6KA3 | |
| SCHEMBL15249214 | 0.67 | CDK2 (0.54) | CDK2CCNE1CDK4CCND1RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | CDK2 69/4885CCNE1 58/4885CDK4 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.